# TaiRx

Source: https://onco.cc/companies/tairx/  
OnCo record `tairx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TaiRx is a Taiwan-based biotechnology company that leads 3 cancer trials in OnCo, testing the oral anti-cancer agent CVM-1118 (foslinanib) in hepatocellular carcinoma, neuroendocrine tumours, pancreatic ductal adenocarcinoma and advanced solid tumours.

## Summary

TaiRx is a Taipei-based new drug development company. Its lead candidate CVM-1118 (foslinanib) is an oral anti-cancer agent in phase 2 for neuroendocrine tumours and hepatocellular carcinoma, and it also markets Zelnite, an injectable selenium product approved in Taiwan. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07521852 (phase 2, A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and...), NCT05257590 (phase 2, CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma) and NCT03600233 (phase 2, Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: 台睿生物科技
- Tags: ctgov-sponsor
- HQ: Taipei
- Type: biotech
- Website: https://www.trx.com.tw
- Ticker: TPEx:6580

## Sources

- Official website: https://www.trx.com.tw
- ClinicalTrials.gov: trials led by TaiRx: https://clinicaltrials.gov/search?lead=TaiRx%2C%20Inc.

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- trials: [A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part](https://onco.cc/trials/nct07521852/), [CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma](https://onco.cc/trials/nct05257590/), [Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors](https://onco.cc/trials/nct03600233/)

---
JSON: https://onco.cc/api/v1/entities/tairx.json